Equine & Livestock

2023 AAEP Buyers Guide

Issue link: https://www.e-digitaleditions.com/i/1510011

Contents of this Issue

Navigation

Page 20 of 39

Feel confident in their comfort EQUIOXX ® is registered trademarks of Boehringer Ingelheim Animal Health USA, Inc. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-EQU-0392-2022-A 1 EQUIOXX product labels and FOI summaries and supplements 2 Kvaternik V, Pollmeier M, et al, Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib in horses. J Vet Pharmacol Ther. 2007;30(3):208-217. IMPORTANT SAFETY INFORMATION: As with any prescription medication, prior to use, a veterinarian should perform a physical examination and review the horse's medical history. A veterinarian should advise horse owners to observe for signs of potential drug toxicity. As a class, nonsteroidal anti-inflammatory drugs may be associated with gastrointestinal, hepatic and renal toxicity. Use with other NSAIDs, corticosteroids or nephrotoxic medication should be avoided. EQUIOXX has not been tested in horses less than 1 year of age or in breeding horses, or pregnant or lactating mares. EQUIOXX ® (firocoxib) HAS MORE SAFETY DATA THAN ANY OTHER NSAID. 1,2 For a horse, joint disease means living in the shadow of its former self. EQUIOXX helps them escape the shadows with up to 24 hours of pain relief in just one dose 1 . Talk to your clients about EQUIOXX. To explore the full Free To Move joint health portfolio visit THEARTOFHORSE.COM

Articles in this issue

Links on this page

Archives of this issue

view archives of Equine & Livestock - 2023 AAEP Buyers Guide